15
Participants
Start Date
August 4, 2020
Primary Completion Date
April 8, 2021
Study Completion Date
August 11, 2022
ZL-2306(Niraparib）
The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Beijing Cancer Hospital, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou
Harbin Medical University, Haerbin
Fudan University Shanghai Cancer Center, Shanghai
West China Second Iniversity Hospital, Chengdu
Sir Run Shaw Hospital, school of medicine, Zhejiang University, Guangzhou
Zai Lab (Shanghai) Co., Ltd.
INDUSTRY